What are the microscopic findings of left atrial myxoma, including the cells involved?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Microscopic Findings of Left Atrial Myxoma

Left atrial myxomas are characterized microscopically by polygonal to stellate-shaped myxoma cells (lepidic cells) with abundant eosinophilic cytoplasm embedded within a loose, gelatinous myxoid stroma rich in acid mucopolysaccharides. 1, 2

Cellular Components

Myxoma Cells (Lepidic Cells)

  • Polygonal to stellate-shaped cells with abundant eosinophilic cytoplasm arranged singly or in small clusters within the myxoid matrix 1, 2
  • These cells are active cells of endothelial origin based on electron microscopic studies 3
  • The cells are sparse and distributed throughout an extensive mucoid stroma 4

Stromal Cells

  • Spindle-shaped cells embedded within the abundant myxoid matrix 2
  • These cells contribute to the structural framework of the tumor 2

Endothelial Cells

  • Line the vascular channels within the tumor 2
  • Partially cover the tumor surface along with myxoma cells 5

Extracellular Matrix and Stroma

Myxoid Matrix Characteristics

  • Abundant loose, gelatinous extracellular matrix that appears basophilic on H&E staining 1, 2
  • Rich in acid mucopolysaccharides, specifically hyaluronic acid and chondroitin sulfate 1
  • This mucopolysaccharide-rich spongiosa creates the characteristic myxomatous appearance 6

Vascular Elements

Blood Vessel Architecture

  • Thin-walled blood vessels of varying caliber scattered throughout the tumor 1, 2
  • Highly vascularized areas within the myxoid stroma 7
  • Occasional thrombosis within tumor vessels 1

Hemorrhagic Features

  • Hemorrhage and hemosiderin deposition are common findings, especially in larger tumors 1, 2
  • These features reflect the friable nature of the tumor vasculature 4

Surface Characteristics

Surface Architecture

  • Friable, gelatinous surface with adherent thrombus that serves as a source of embolic potential 2, 4
  • Villous or papillary surface architecture in some cases, which is associated with higher embolic risk and greater embolic potential 1, 2
  • Surface partially covered by myxoma cells and partly by endothelial cells 5

Immunohistochemical Profile

Positive Markers

  • Vimentin (consistently positive) 2
  • Calretinin (positive) 2
  • PGP 9.5 (positive in 75% of cases) 5
  • S100 antigen (positive in 67% of cases) 5
  • Neurone specific enolase (NSE) (positive in 50% of cases) 5

Negative Markers

  • Cytokeratin (negative) 2
  • S100 (negative in standard panels, though some studies show variable positivity) 2

Important Clinical Correlations

Embolic Potential

  • The friable surface with adherent thrombus creates a 25% overall embolism rate in untreated patients 1, 2
  • More villous tumor morphology indicates greater embolic potential and urgency for surgical intervention 1

Histologic Distinction

  • These microscopic features are histologically and histochemically different from left atrial thrombi, which is critical for accurate diagnosis 3
  • The presence of abundant basophil cell infiltration and pericellular type IV collagen creates appearances similar to nerve sheath tumors (neurofibromas) 5

References

Guideline

Diagnosis and Management of Left Atrial Mass with Syncope

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosis and Management of Left Atrial Mass with Syncope

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Atrial myxoma: a tumour in search of its origins.

British heart journal, 1992

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.